Andere talen Akili, Inc.

Aandelen

AKLI

US00974B1070

slotkoers Nasdaq Andere beurzen 00:00:00 14-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,4225 ^USD	0,00%		+0,55%	-13,26%

14/05	Akili, Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
30/04	Akili, Inc. is van plan door te gaan met het verkrijgen van toestemming van de U.S. Food and Drug Administration voor het op de markt brengen van het EndeavorOTC-product	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. - AKLI	05/06
AKLI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akili, Inc. Is Fair to Shareholders	03/06
Shareholder Alert: Ademi LLP investigates whether Akili, Inc. has obtained a Fair Price for its Public Shareholders	29/05
PureTech Health's Akili, Virtual Therapeutics Sign Merger Deal to Launch Digital Health Company	29/05
Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company	29/05
Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. for $35 million.	29/05
Akili, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Earnings Flash (AKLI) AKILI Posts Q1 Revenue $383,000, vs. Street Est of $0.8M	14/05
Akili Reports First Quarter 2024 Financial Results and Provides Business Update	14/05
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results	30/04
Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product	30/04
Akili, Inc. to Reduce Workforce	30/04
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	30/04
Akili, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Akili, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Earnings Flash (AKLI) AKILI Posts Q4 Revenue $749,000, vs. Street Est of $0.78M	29/02
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	29/02
PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan	28/02
Shionogi & Co., Ltd. - Positive Results from Phase 3 Clinical trial of Digital Therapeutic App SDT-001 and Submission for Marketing Approval in Japan	27/02
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan	27/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Akili, Inc.

Aandelen

AKLI

US00974B1070

Andere talen

Filters